Zdrowie i gospodarka · 30/05/2012

FDA Releases Draft Guidance on Accelerated Approval for Breast Cancer Treatment

The FDA has released a draft guidance to help pharmaceutical companies design clinical trials for new breast cancer treatments using pathologic complete response as a surrogate endpoint to support accelerated approval, aiming to address the unmet medical needs of high-risk breast cancer patients.